Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

Research output: Contribution to journalJournal articleResearchpeer-review


  1. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Human endogenous retroviruses and their implication for immunotherapeutics of cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development of Sarcopenia in Patients With Bladder Cancer: A Systematic Review

    Research output: Contribution to journalReviewpeer-review

  2. Status of Metastatic Bladder Cancer Treatment Illustrated by a Case

    Research output: Contribution to journalReviewpeer-review

  • A Horwich
  • M Babjuk
  • J Bellmunt
  • H M Bruins
  • T M De Reijke
  • M De Santis
  • S Gillessen
  • N James
  • S Maclennan
  • J Palou
  • T Powles
  • M J Ribal
  • S F Shariat
  • T Van Der Kwast
  • E Xylinas
  • N Agarwal
  • T Arends
  • A Bamias
  • A Birtle
  • P C Black
  • B H Bochner
  • M Bolla
  • J L Boormans
  • A Bossi
  • A Briganti
  • I Brummelhuis
  • M Burger
  • D Castellano
  • R Cathomas
  • A Chiti
  • A Choudhury
  • E Compérat
  • S Crabb
  • S Culine
  • B De Bari
  • W De Blok
  • P J L De Visschere
  • K Decaestecker
  • K Dimitropoulos
  • J L Dominguez-Escrig
  • S Fanti
  • V Fonteyne
  • M Frydenberg
  • J J Futterer
  • G Gakis
  • B Geavlete
  • P Gontero
  • B Grubmüller
  • S Hafeez
  • D E Hansel
  • A Hartmann
  • D Hayne
  • A M Henry
  • V Hernandez
  • H Herr
  • K Herrmann
  • P Hoskin
  • J Huguet
  • B A Jereczek-Fossa
  • R Jones
  • A M Kamat
  • V Khoo
  • A E Kiltie
  • S Krege
  • S Ladoire
  • P C Lara
  • A Leliveld
  • E Linares-Espinós
  • V Løgager
  • A Lorch
  • Y Loriot
  • R Meijer
  • M Carmen Mir
  • M Moschini
  • H Mostafid
  • A-C Müller
  • C R Müller
  • J N'Dow
  • A Necchi
  • Y Neuzillet
  • J R Oddens
  • J Oldenburg
  • S Osanto
  • W J G Oyen
  • L Pacheco-Figueiredo
  • H Pappot
  • M I Patel
  • B R Pieters
  • K Plass
  • M Remzi
  • M Retz
  • J Richenberg
  • M Rink
  • F Roghmann
  • J E Rosenberg
  • M Rouprêt
  • O Rouvière
  • C Salembier
  • A Salminen
  • P Sargos
  • S Sengupta
  • A Sherif
  • R J Smeenk
  • A Smits
  • A Stenzl
  • G N Thalmann
  • B Tombal
  • B Turkbey
  • S Vahr Lauridsen
  • R Valdagni
  • A G Van Der Heijden
  • H Van Poppel
  • M D Vartolomei
  • E Veskimäe
  • A Vilaseca
  • F A Vives Rivera
  • T Wiegel
  • P Wiklund
  • A Williams
  • R Zigeuner
  • J A Witjes
View graph of relations

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.

OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.

DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.

SETTING: Online Delphi survey and consensus conference.

PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).

RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.

CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

Original languageEnglish
JournalAnnals of Oncology
Issue number11
Pages (from-to)1697-1727
Number of pages31
Publication statusPublished - 1 Nov 2019

ID: 58931520